Securian Asset Management Inc. Reduces Stock Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Securian Asset Management Inc. cut its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 2.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,256 shares of the medical equipment provider’s stock after selling 140 shares during the period. Securian Asset Management Inc.’s holdings in Lantheus were worth $470,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Wilmington Savings Fund Society FSB purchased a new stake in shares of Lantheus during the 3rd quarter valued at approximately $25,000. Kestra Investment Management LLC purchased a new stake in Lantheus in the fourth quarter valued at $27,000. UMB Bank n.a. lifted its stake in shares of Lantheus by 31.5% in the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock valued at $50,000 after purchasing an additional 134 shares during the last quarter. Parkside Financial Bank & Trust grew its holdings in shares of Lantheus by 49.4% during the 4th quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider’s stock worth $76,000 after purchasing an additional 280 shares during the period. Finally, GAMMA Investing LLC increased its position in shares of Lantheus by 118.0% during the 4th quarter. GAMMA Investing LLC now owns 1,018 shares of the medical equipment provider’s stock worth $91,000 after purchasing an additional 551 shares during the last quarter. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Trading Up 1.6 %

NASDAQ:LNTH opened at $102.76 on Tuesday. Lantheus Holdings, Inc. has a 12-month low of $56.44 and a 12-month high of $126.89. The firm has a market cap of $7.04 billion, a PE ratio of 17.10 and a beta of 0.38. The stock has a fifty day moving average price of $92.25 and a 200 day moving average price of $96.67.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The company had revenue of $391.11 million during the quarter, compared to analysts’ expectations of $376.61 million. Equities analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on LNTH. Truist Financial increased their target price on shares of Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a research note on Thursday, February 27th. StockNews.com downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. The Goldman Sachs Group initiated coverage on Lantheus in a research note on Wednesday, December 18th. They set a “buy” rating and a $143.00 price target on the stock. Finally, JMP Securities reiterated a “market outperform” rating and issued a $112.00 price objective on shares of Lantheus in a report on Tuesday, January 14th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $132.86.

Insiders Place Their Bets

In other news, Director Mary Anne Heino sold 53,107 shares of Lantheus stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the sale, the director now directly owns 440,399 shares of the company’s stock, valued at approximately $41,551,645.65. The trade was a 10.76 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director James H. Thrall sold 1,000 shares of the stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the transaction, the director now directly owns 33,207 shares in the company, valued at $3,146,695.32. This trade represents a 2.92 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 54,109 shares of company stock worth $5,105,606 in the last 90 days. Corporate insiders own 1.50% of the company’s stock.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.